Deep search
Search
Images
Copilot
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ($CVS) and Cigna
FTC finds top 3 PBMs inflated drug prices by $7.3B
The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.
FTC finds PBMs excessively marked up prices on specialty drugs
A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.
22h
on MSN
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The report is the latest indictment of America’s broken healthcare system.
1d
on MSN
FTC accuses CVS, Cigna, UnitedHealth of abusing middleman role, shares down
Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) ...
23h
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Modern Healthcare
2d
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
1d
on MSN
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
1d
on MSN
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Healthcare Dive
1d
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
BioPharma Dive
2d
FTC again goes after PBMs’ business practices in new report
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...
1d
on MSN
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Healthcare Dive
7d
CVS successfully converts commercial pharmacy contracts to “cost plus” model
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
Modern Healthcare
10d
Where smaller PBMs are headed this year
Newer entrants to the pharmacy benefit management market will continue to face stiff competition in 2025 as they seek more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback